lactic acid has been researched along with Erythema in 18 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although rosacea and seborrheic dermatitis share some symptoms of sensitive skin, whether they respond differently to lactic acid sting and capsaicin tests, common tests for diagnosis of sensitive skin, is unknown." | 8.31 | Rosacea and seborrheic dermatitis differentially respond to lactic acid sting and capsaicin tests in Chinese women. ( Gu, H; He, L; He, Y; Hu, M; Man, MQ; Tu, Y; Wu, P, 2023) |
| "To evaluate the efficiency and adverse effects of 10% all-trans retinol (ROL) gel for improvement of skin hyperpigmentation." | 5.10 | Clinical trial of bleaching treatment with 10% all-trans retinol gel. ( Aiba, E; Aoyama, T; Harii, K; Iga, T; Matsumoto, D; Mitoma, Y; Momosawa, A; Sato, K; Yoshimura, K, 2003) |
| "Although rosacea and seborrheic dermatitis share some symptoms of sensitive skin, whether they respond differently to lactic acid sting and capsaicin tests, common tests for diagnosis of sensitive skin, is unknown." | 4.31 | Rosacea and seborrheic dermatitis differentially respond to lactic acid sting and capsaicin tests in Chinese women. ( Gu, H; He, L; He, Y; Hu, M; Man, MQ; Tu, Y; Wu, P, 2023) |
| "We studied the mechanism by which fermented milk ameliorates UV-B-induced skin damage and determined the active components in milk fermented with lactic acid bacteria by evaluating erythema formation, dryness, epidermal proliferation, DNA damage and cytokine mRNA levels in hairless mice exposed to acute UV-B irradiation." | 3.85 | Exopolysaccharides Isolated from Milk Fermented with Lactic Acid Bacteria Prevent Ultraviolet-Induced Skin Damage in Hairless Mice. ( Fukasawa, T; Ichihashi, M; Kitade, M; Morifuji, M; Yamaji, T, 2017) |
| "For the glabellar region, severe partly vascular adverse events have been reported after treatment with injectable fillers." | 1.35 | The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study. ( Bachmann, F; Erdmann, R; Hartmann, V; Rzany, B; Wiest, L, 2009) |
| "Biotin deficiency associated with total parenteral nutrition is an emerging clinical problem; criteria for diagnosis and dosage for treatment are unclear." | 1.27 | Biotin deficiency complicating parenteral alimentation: diagnosis, metabolic repercussions, and treatment. ( Baker, H; Baswell, DL; Holman, RT; Mock, DM; Sweetman, L, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Shu, X | 1 |
| Zhao, S | 1 |
| Huo, W | 1 |
| Tang, Y | 1 |
| Zou, L | 1 |
| Li, Z | 1 |
| Li, L | 1 |
| Wang, X | 1 |
| Hu, M | 1 |
| Tu, Y | 1 |
| Man, MQ | 1 |
| He, Y | 1 |
| Wu, P | 1 |
| He, L | 1 |
| Gu, H | 1 |
| Morifuji, M | 1 |
| Kitade, M | 1 |
| Fukasawa, T | 1 |
| Yamaji, T | 1 |
| Ichihashi, M | 1 |
| Bachmann, F | 1 |
| Erdmann, R | 1 |
| Hartmann, V | 1 |
| Wiest, L | 1 |
| Rzany, B | 1 |
| Cox, SE | 1 |
| Kojic, Z | 1 |
| Stojanovic, D | 1 |
| Popadic, S | 1 |
| Jokanovic, M | 1 |
| Janackovic, D | 1 |
| Cho, HJ | 1 |
| Chung, BY | 1 |
| Lee, HB | 1 |
| Kim, HO | 1 |
| Park, CW | 1 |
| Lee, CH | 1 |
| Yoshimura, K | 1 |
| Momosawa, A | 1 |
| Aiba, E | 1 |
| Sato, K | 1 |
| Matsumoto, D | 1 |
| Mitoma, Y | 1 |
| Harii, K | 1 |
| Aoyama, T | 1 |
| Iga, T | 1 |
| Basketter, DA | 2 |
| Griffiths, HA | 1 |
| Reed, JT | 1 |
| Joseph, AK | 1 |
| Bridenstine, JB | 1 |
| Coverly, J | 1 |
| Peters, L | 1 |
| Whittle, E | 1 |
| Elsner, P | 1 |
| Wigger-Alberti, W | 1 |
| Pantini, G | 1 |
| Muizzuddin, N | 1 |
| Marenus, KD | 1 |
| Maes, DH | 1 |
| Jennings, MB | 1 |
| Logan, L | 1 |
| Alfieri, DM | 1 |
| Ross, CF | 1 |
| Goodwin, S | 1 |
| Lesczczynski, C | 1 |
| Demas, PN | 1 |
| Braun, TW | 1 |
| Odio, M | 1 |
| Streicher-Scott, J | 1 |
| Hansen, RC | 1 |
| Uchida, M | 1 |
| Jin, Y | 1 |
| Natsume, H | 1 |
| Kobayashi, D | 1 |
| Sugibayashi, K | 1 |
| Morimoto, Y | 1 |
| Mock, DM | 1 |
| Baswell, DL | 1 |
| Baker, H | 1 |
| Holman, RT | 1 |
| Sweetman, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Split-face Study of Changing in Skin Physiology and Clinical Appearance After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces[NCT02312154] | Phase 4 | 25 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Single Center Clinical Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris[NCT03128723] | 45 participants (Actual) | Interventional | 2017-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"We measured a elasticity by a reviscometer device (Courage & Khazaka, Cologne, Germany).~The range of elasticity was 0 (most elastic possible as) ~400 AU(Arbitrary Unit) (inelastic as possible)" (NCT02312154)
Timeframe: 12 weeks
| Intervention | AU (arbitrary unit) (Mean) |
|---|---|
| Treated Side (Restylane Vital) | 242.33 |
| Untreated Side | 271.15 |
"We measured an erythema index by a mexameter device (Courage & Khazaka, Cologne, Germany).~The range of erythema index is 0~999 AU(Arbitrary Unit). The range of erythema index was 0 (as non-erythematous as possible) ~999 AU (most erythematous possible)" (NCT02312154)
Timeframe: 12 weeks
| Intervention | AU (arbitrary unit) (Mean) |
|---|---|
| Treated Side (Restylane Vital) | 253.66 |
| Untreated Side | 243.53 |
The therapeutic outcome was assessed by investigator using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse. (NCT02312154)
Timeframe: 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Treated Side (Restylane Vital) | 1.38 |
| Untreated Side | 0 |
The therapeutic outcome was assessed by patient self-assessment using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse (NCT02312154)
Timeframe: 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Treated Side (Restylane Vital) | 1.33 |
| Untreated Side | 0 |
"We measured a hydration level by a corneometer device (Courage & Khazaka, Cologne, Germany).~The range of hydration level was 0 (as dry as possible) ~120 AU (Arbitrary Unit)(most moist possible)" (NCT02312154)
Timeframe: 12 weeks
| Intervention | AU (arbitrary unit) (Mean) |
|---|---|
| Treated Side (Restylane Vital) | 53.19 |
| Untreated Side | 46.75 |
"We measured a melanin index by a mexameter device (Courage & Khazaka, Cologne, Germany).~The range of melanin index was 0 (as bright as possible) ~999 AU (Arbitrary Unit) (most dark possible)." (NCT02312154)
Timeframe: 12 weeks
| Intervention | AU (arbitrary unit) (Mean) |
|---|---|
| Treated Side (Restylane Vital) | 147.25 |
| Untreated Side | 149.00 |
Cutaneous Tolerance Scores: Burning/Stinging (assessing skin burning/stinging), from Baseline to Day 14. Scale range is 0-3 where 0 = no burning/stinging, 1 = mild burning/stinging, 2 = moderate burning/stinging, and 3 = severe burning/stinging. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.02 |
Cutaneous Tolerance Scores: Burning/Stinging (assessing skin burning/stinging), from Baseline to Day 28. Scale range is 0-3 where 0 = no burning/stinging, 1 = mild burning/stinging, 2 = moderate burning/stinging, and 3 = severe burning/stinging. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Dryness/Scaling (assessing skin dryness), from Baseline to Day 14. Scale range is 0-3, where 0 = no dryness, 1 = mild dryness, 2 = moderate dryness, and 3 = severe dryness. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.11 |
Cutaneous Tolerance Scores: Dryness/Scaling (assessing skin dryness), from Baseline to Day 28. Scale range is 0-3, where 0 = no dryness, 1 = mild dryness, 2 = moderate dryness, and 3 = severe dryness. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.14 |
Cutaneous Tolerance Scores: Edema (assessing skin edema/swelling), from Baseline to Day 14. Scale range is 0-3 where 0 = no edema, 1 = mild edema, 2 = moderate edema, and 3 = severe edema. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Edema (assessing skin edema/swelling), from Baseline to Day 28. Scale range is 0-3 where 0 = no edema, 1 = mild edema, 2 = moderate edema, and 3 = severe edema. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Erythema (assessing skin redness), from Baseline to Day 14. Scale range is 0-3 where 0 = no redness, 1 = mild redness, 2 = moderate redness, and 3 = severe redness. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.09 |
Cutaneous Tolerance Scores: Erythema (assessing skin redness), from Baseline to Day 28. Scale range is 0-3 where 0 = no redness, 1 = mild redness, 2 = moderate redness, and 3 = severe redness. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.07 |
Cutaneous Tolerance Scores: Itching (assessing skin itching), from Baseline to Day 14. Scale range is 0-3 where 0 = no itching, 1 = mild itching, 2 = moderate itching, and 3 = severe itching. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.04 |
Cutaneous Tolerance Scores: Itching (assessing skin itching), from Baseline to Day 28. Scale range is 0-3 where 0 = no itching, 1 = mild itching, 2 = moderate itching, and 3 = severe itching. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | 0.00 |
Cutaneous Tolerance Scores: Tightness/Dry Feeling (assessing skin tightness/dry feeling), from Baseline to Day 14. Scale range is 0-3 where 0 = no tightness/dry feeling, 1 = mild tightness/dry feeling, 2 = moderate tightness/dry feeling, and 3 = severe tightness/dry feeling. (NCT03128723)
Timeframe: Baseline to Day 14
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.02 |
Cutaneous Tolerance Scores: Tightness/Dry Feeling (assessing skin tightness/dry feeling), from Baseline to Day 28. Scale range is 0-3 where 0 = no tightness/dry feeling, 1 = mild tightness/dry feeling, 2 = moderate tightness/dry feeling, and 3 = severe tightness/dry feeling. (NCT03128723)
Timeframe: Baseline to Day 28
| Intervention | Units on a scale (Mean) |
|---|---|
| Acne Mask | -0.05 |
3 trials available for lactic acid and Erythema
| Article | Year |
|---|---|
Clinical trial of bleaching treatment with 10% all-trans retinol gel.
Topics: Adult; Aged; Ascorbic Acid; Dermatitis, Irritant; Drug Therapy, Combination; Erythema; Female; Gels; | 2003 |
Perfluoropolyethers in the prevention of irritant contact dermatitis.
Topics: Caustics; Dermatitis, Irritant; Emulsions; Erythema; Ethers; Female; Fluorocarbons; Humans; Irritant | 1998 |
A comparative study of lactic acid 10% and ammonium lactate 12% lotion in the treatment of foot xerosis.
Topics: Adult; Aged; Aged, 80 and over; Dermatologic Agents; Double-Blind Method; Erythema; Female; Foot Der | 2002 |
15 other studies available for lactic acid and Erythema
| Article | Year |
|---|---|
Clinical study of a spray containing birch juice for repairing sensitive skin.
Topics: Betula; Erythema; Humans; Lactic Acid; Skin; Water | 2023 |
Rosacea and seborrheic dermatitis differentially respond to lactic acid sting and capsaicin tests in Chinese women.
Topics: Capsaicin; Dermatitis, Seborrheic; East Asian People; Erythema; Female; Humans; Lactic Acid; Rosacea | 2023 |
Exopolysaccharides Isolated from Milk Fermented with Lactic Acid Bacteria Prevent Ultraviolet-Induced Skin Damage in Hairless Mice.
Topics: Animals; Cell Proliferation; Cytokines; DNA Damage; Erythema; Female; Fermentation; Lactic Acid; Mic | 2017 |
The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study.
Topics: Adult; Aged; Aged, 80 and over; Biocompatible Materials; Cicatrix; Dermatologic Agents; Drug Combina | 2009 |
Clinical experience with filler complications.
Topics: Acne Keloid; Adult; Aged; Anti-Bacterial Agents; Biocompatible Materials; Dermatologic Agents; Drug | 2009 |
The irritative property of alpha-tricalcium phosphate to the rabbit skin.
Topics: Administration, Topical; Animals; Calcium Phosphates; Edema; Erythema; Female; Lactic Acid; Male; Oi | 2009 |
Quantitative study of stratum corneum ceramides contents in patients with sensitive skin.
Topics: Adult; Back; Ceramides; Erythema; Face; Female; Forearm; Hand; Humans; Lactic Acid; Leg; Male; Pain; | 2012 |
A study of the relationship between susceptibility to skin stinging and skin irritation.
Topics: Erythema; Female; Humans; Irritants; Lactates; Lactic Acid; Male; Pain Threshold; Paresthesia; Patch | 1993 |
Treatment of periorbital wrinkles. A comparison of the SilkTouch carbon dioxide laser with a medium-depth chemical peel.
Topics: Administration, Cutaneous; Adult; Aged; Carbon Dioxide; Chemexfoliation; Cicatrix; Drug Combinations | 1997 |
Susceptibility to skin stinging, non-immunologic contact urticaria and acute skin irritation; is there a relationship?
Topics: Acrolein; Acute Disease; Administration, Topical; Adult; Anti-Inflammatory Agents; Antimutagenic Age | 1998 |
Factors defining sensitive skin and its treatment.
Topics: Adult; Balsams; Cosmetics; Dermatitis, Contact; Dermatologic Agents; Epidermis; Erythema; Exanthema; | 1998 |
Chemical skin resurfacing.
Topics: Anesthesia, Local; Chemexfoliation; Cicatrix; Dermatologic Agents; Dermatologic Surgical Procedures; | 1998 |
Disposable baby wipes: efficacy and skin mildness.
Topics: Adolescent; Adult; Clinical Trials as Topic; Diaper Rash; Erythema; Female; Household Products; Huma | 2001 |
Introduction of poly-L-lactic acid microspheres into the skin using supersonic flow: effects of helium gas pressure, particle size and microparticle dose on the amount introduced into hairless rat skin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biodegradation, Environmental; Drug Carriers; Eryt | 2002 |
Biotin deficiency complicating parenteral alimentation: diagnosis, metabolic repercussions, and treatment.
Topics: Alopecia; Biotin; Citrates; Diagnosis, Differential; Erythema; Fatty Acids, Essential; Female; Glyci | 1985 |